Additional Information

Description

Labetalol HCl 5 mg/mL Multi-Dose Vial, manufactured by Hikma Pharmaceuticals Plc, provides a potent treatment option for hypertension management. This medication, labeled as Labetalol Hydrochloride Injection, USP, acts as an adrenergic receptor blocking agent, exhibiting both selective alpha1-adrenergic and nonselective beta-adrenergic receptor blocking actions within a single substance.

Designed for intravenous administration in hospitalized patients, the dosage of Labetalol HCl Injection must be individualized based on the severity of hypertension and the patient's response to dosing. This formulation is specifically indicated for the control of blood pressure in cases of severe hypertension, where rapid and effective management is essential for patient well-being.

Each vial contains 20 mL of the solution and is packaged individually, providing convenience and accuracy in dosing. By offering a reliable solution for blood pressure control in critical care settings, Labetalol HCl Injection by Hikma Pharmaceuticals Plc ensures optimal patient care and management of hypertensive emergencies.